Search PubMedSearch

Biomedical subjects

Yifan Zhang

Publications and source records attributed to Yifan Zhang.

3 recordsLinked to original sources

Controlled framework nickel exsolution in metal-organic frameworks creates confined active sites for chemoselective citral hydrogenation.

Selective hydrogenation of citral to citronellal over non-noble-metal catalysts remains challenging because highly active metallic Ni simultaneously promotes efficient substrate activation and undesired over‑hydrogenation of the desired product. Herein, we develop a controlled exsolution strategy in waste polyethylene terephthalate (PET)-derived nickel metal-organic frameworks (Ni-MOFs) to transform framework Ni into confined metallic active sites while preserving the porous framework architecture. During reductive treatment, framework Ni2+ species undergo gradual node-to-metal evolution, generating highly dispersed Ni0 sites confined within the partially retained MOF framework. More importantly, the degree of framework Ni exsolution governs the balance between citral activation and citronellal over‑hydrogenation, thereby establishing a distinct chemoselective window. Within the optimal exsolution regime, the framework-confined Ni0 sites enable efficient H2 activation and selective hydrogenation of the CC bond while suppressing the subsequent hydrogenation of citronellal. Consequently, the optimized catalyst achieves ∼99% citral conversion and 100% citronellal selectivity at 90 °C and 2 MPa H2, together with excellent catalytic stability and recyclability. Beyond the sustainable valorization of waste PET, this work establishes controlled framework exsolution as an effective strategy for engineering confined active sites and regulating chemoselectivity in non-noble-metal hydrogenation catalysts.

Chemoselective hydrogenation

Systemic Proteomic Alterations and Predictive Biomarkers of Paroxetine Response in Refractory Rosacea: A Secondary Analysis of a Randomized Clinical Trial.

IMPORTANCE: Rosacea is a chronic inflammatory cutaneous disorder characterized by persistent erythema and vascular dysregulation. While paroxetine has shown clinical efficacy in reducing these symptoms, the systemic molecular mechanisms underlying its therapeutic response remain poorly characterized. OBJECTIVE: To investigate systemic proteomic alterations and identify potential predictive biomarkers in patients with refractory erythematous rosacea following paroxetine treatment. DESIGN, SETTING, AND PARTICIPANTS: This prospective plasma proteomic analysis was nested within a multicenter, randomized, double-blind, placebo-controlled clinical trial (Prospective Rosacea Refractory Erythema Randomized Clinical Trial [PRRERCT]). Participants included patients aged 18 to 65 years with refractory rosacea (Clinician's Erythema Assessment [CEA] score &#x2265;3). Plasma samples were collected at baseline and after 12 weeks of treatment. The data for this study were analyzed between September 2025 and November 2025. INTERVENTIONS: Participants received oral paroxetine, 25 mg per day, for a 12-week treatment period. MAIN OUTCOMES AND MEASURES: Systemic protein expression profiles were analyzed using data-independent acquisition liquid chromatography-tandem mass spectrometry. Clinical response was evaluated using CEA and the Flushing Assessment Tool. Correlations between proteomic changes and clinical improvements were assessed, and predictive biomarkers were identified using receiver operating characteristic curve analysis. RESULTS: Among 24 participants (mean [SD] age, 35 [11] years; 24 [100%] female), paroxetine treatment significantly reduced mean (SD) CEA scores from 3.1 (0.3) to 2.3 (0.7) and Flushing Assessment Tool scores from 3.1 (0.6) to 2.0 (0.9) (P&#x2009;<&#x2009;.001). Exploratory proteomic analysis revealed 497 candidate differentially expressed proteins after treatment. Downregulated proteins showed preliminary enrichment in pathways related to immune response activation, insulin receptor signaling, and neuronal remodeling. A subset of 98 reversed-response proteins was observed, primarily linked to synaptic vesicle cycles and vascular smooth muscle contraction. Proteomic alterations were associated with clinical improvement (65 proteins for erythema; 73 for flushing). Candidate biomarkers, notably OLFML3 (area under the receiver operating characteristic curve [AUC], 0.87 [95% CI, 0.70-1.00]) and IGFBP2 (AUC, 0.80 [95% CI 0.55-1.00]), demonstrated high predictive value for clinical response. CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, paroxetine treatment was associated with modulation of systemic neuro-vascular-immune networks in patients with rosacea. These exploratory findings provide preliminary mechanistic clues regarding the possible disease-modifying potential of paroxetine and point to circulating protein signatures that may facilitate personalized therapeutic strategies for rosacea management. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2000031479.

Humans

A New Threat Emerges: The First Detection of GVIII Genotype IBV in China and the Urgent Need for Molecular Surveillance.

In 2025, an infectious bronchitis virus (IBV) strain of the GVIII genotype was identified and isolated from a poultry farm in Hebei Province, China, representing the first documented detection of this IBV genotype within the country to date. Nucleotide homology analysis revealed that the S1 gene of this isolate shares 62.2%-96.9% sequence identity with previously reported GVIII-type strains from other countries. Comprehensive phylogenetic analysis of the complete genome indicated that this strain originated from a single recombination event: Its S gene may have been derived from the GVIII-1 lineage strain IBV/Ck/USA/CA/21-1883, while the remaining genomic regions were likely acquired from the GI-19 lineage strain SD. Pathogenicity evaluation demonstrated that infected flocks exhibited reduced body weight gain, with 40% of chickens showing signs of diarrhea. Necropsy findings included hemorrhagic lesions at the proventriculus-gizzard junction and within the bursa of Fabricius. Moreover, 85% of infected hens developed severe oviduct hypoplasia, and 90% showed a reduction in follicular number. The isolate described in this study constitutes the first detection of a GVIII genotype IBV strain in China, although its route of introduction remains undetermined. The emergence of this strain highlights the necessity for sustained molecular surveillance of IBV and the development of genotype-matched vaccines.

Animals